IP Library › Granted Patent US 9,457,074
Granted Patent B2
US 9,457,074 · App. 14/628,358 · Granted Oct 4, 2016

Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome

Inventors: Renukaradhya J. Gourapura (Wooster, OH); Varun Dwivedi (Columbus, OH); Basavaraj S. Binjawadagi (Wooster, OH); Jordi Torrelles (Dublin, OH)
Assignee: Ohio State Innovation Foundation
A61K39/12A61K9/14A61K35/74A61K35/76A61K39/385A61K39/39C07K16/10C12N7/00A61K9/5153A61K2039/5252A61K2039/5258A61K2039/541A61K2039/543A61K2039/545A61K2039/552A61K2039/55544A61K2039/55555A61K2039/55594A61K2039/57A61K2039/58A61K2039/6018A61K2039/6087A61K2039/6093B82Y5/00C12N2770/10021C12N2770/10034C12N2770/10061C12N2770/10071
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,457,074
App. No.
14/628,358
Granted
Oct 4, 2016
Kind
B2
Abstract

Disclosed herein are methods and compositions for treating or preventing Porcine reproductive and respiratory syndrome (PRRS) infection in a subject.

Claims (22)

1. A composition comprising an inactivated porcine reproductive and respiratory syndrome virus (PRRSV) entrapped within a nanoparticle, wherein the composition further comprises an adjuvant, wherein the adjuvant comprises a Mycobacterium lysate.

2. The composition of claim 1 , wherein the adjuvant is a Mycobacterium tuberculosis whole cell lysate.

3. The composition of claim 1 , wherein the adjuvant is selected from the group consisting of a Mycobacterium smegmatis whole cell lysate, Mycobacterium tuberculosis whole cell lysate, and Mycobacterium vaccae whole cell lysate.

4. The composition of claim 1 , wherein the nanoparticle is immunogenic.

5. The composition of claim 1 , wherein the inactivated PRRSV is entrapped within the nanoparticle by a water/oil/water emulsion method.

6. The composition of claim 1 , wherein the nanoparticle is poly(lactide co-glycolide) (PLGA).

7. The composition of claim 6 , wherein the PLGA is 50/50 PLGA.

8. The composition of claim 1 , in a ratio of about 180 mg of PLGA to about 5 mg of inactivated PRRSV.

9. The composition of claim 1 , wherein the inactivated PRRSV is the MN184 strain of PRRSV.

10. The composition of claim 1 , wherein the inactivated PRRSV is inactivated by UV light or binary ethylenimine.

11. A vaccine comprising a composition of claim 1 in a carrier.

12. A method of eliciting an immune response against PRRSV in a pig comprising administering to said pig the vaccine of claim 11 .

13. The method of claim 12 , wherein the immune response is protective against PRRSV infection.

14. A method of reducing reproductive or respiratory failure in a pig comprising

administering to the pig the vaccine of claim 11 to.

15. A method of stimulating an immune response in a pig comprising:

administering to said pig the vaccine of claim 11 .

16. The method of claim 12 , wherein the vaccine is administered at a dose of between 100 ug/pig and 500 ug/pig.

17. The method of claim 12 , wherein the vaccine is administered in a single dose.

18. The method of claim 12 , wherein the vaccine is administered in two doses.

19. The method of claim 18 , wherein the two doses are administered at about two week intervals.

20. The method of claim 12 , wherein the vaccine is administered intranasally.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2015
From: GOURAPURA, RENUKARADHYA J.; DWIVEDI, VARUN; BINJAWADAGI, BASAVARAJ S.; TORRELLES, JORDI
To: OHIO STATE INNOVATION FOUNDATION
Reel/Frame 037211/0042 →
Continuity (3)
Division 13869834 · Apr 24, 2013
Provisional Application 61637547 · Apr 24, 2012
Related Publication 20150265696A1 · Sep 24, 2015